With the real estate beginning to show signs of turning around andinterest rates at record lows, we couldn`t have picked a better time to launchour innovative ideas." Mr. Eckman continued, "As we enter this period of growth and increase awarenessof our company, we wish to see our shareholders benefit as well. I`m confidentthat our efforts to meet the unmet needs of the real estate community will helpus gain recognition among investors and help increase our shareholder base." To sign up for The UpTurn, Inc. private beta, please visit: The UpTurn, Inc The UpTurn, Inc. is developing an innovative online real estate matchmakingexchange and social networking site where real estate market participants arematched with each other, based on their individual profiles and intended rolesin the market.
TheUpTurn will serve all primary residential real estate stakeholders,including would-be buyers, would-be sellers, renters, owners, casual browsers,and real estate enthusiasts, along with professionals including agents andbrokers. TheUpTurn will also directly or indirectly serve all those with avested interest in residential real estate, the home improvement industry, themortgage industry, banks, legal, inspectors, contractors and other realestate-dependent economies. Through , The UpTurn, Inc. offers a pre-launch publicsite for people to connect and share real experiences and perspectives. Realityon Realty supports the exchange of useful, progressive, and honest ideas andinformation about real estate for consumers, professionals, casual observers,and real estate enthusiasts. Forward-Looking Statement: This release may contain forward-looking statements within the meaning ofSection 27A of the Securities Act of 1933, as amended, and Section 21E of theSecurities Exchange Act of 1934, as amended.
All forward-looking statements areinherently uncertain as they are based on current expectations and assumptionsconcerning future events or future performance of the company. Readers arecautioned not to place undue reliance on these forward-looking statements, whichare only predictions and speak only as of the date hereof. Risks anduncertainties applicable to the company and its business could cause thecompany's actual results to differ materially from those indicated in anyforward-looking statements. QualityStocksScottsdale, ArizonaMichael McCarthyOffice: 480-308-0703 Business Wire 2009. MEXICO CITY (Reuters) - Mexico expects a slightly bigger than originally forecast fiscal deficit this year as it factors in government spending to help the economy bounce back from a flu outbreak that paralyzed key industries for nearly a week. Mexico | Swine Flu"It was expected to be about 1.8 percent (of gross domestic product) but it is going to be slightly higher, between 1.9 percent and 2.0 percent," Finance Minister Agustin Carstens told Televisa network.The flu outbreak, which has killed at least 26 people in Mexico, prompted President Felipe Calderon to shut down factories, offices, restaurants and schools. On Wednesday, businesses were expected to slowly restart activity.The halt could knock up to half a percentage point off Mexico's economic growth this year, Carstens predicted on Tuesday.The government has promised tax relief that is seen costing the country a total of 17.4 billion pesos ($1.3 billion) and more than 10 billion pesos in emergency financing from Mexican development banks to lift affected companies.(Reporting by Cyntia Barrera Diaz; Editing by Andrea Ricci) Mexico Swine Flu.
Media contacts: Amylin - Anne EricksonPhone: (858) 754-4443Cell: (858) 349-3195Email: Lilly - Kindra StruppPhone: (317) 277-5170 Cell: (317) 554-9577Email: Alkermes - Rebecca PetersonPhone: (617) 583-6378Cell: (617) 899-2447Email: Exenatide ONCE WEEKLY NEW DRUG APPLICATION SUBMITTEDTO FDA FOR TYPE 2 DIABETES SAN DIEGO, Calif., INDIANAPOLIS, Ind., and CAMBRIDGE, Mass. - May 5, 2009 -Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY)and Alkermes, Inc. (Nasdaq: ALKS) today announced that a New Drug Application(NDA) for exenatide once weekly has been submitted to the U.S Food and DrugAdministration (FDA). Exenatide once weekly is an investigational sustainedrelease medication for type 2 diabetes that is injected subcutaneously andadministered only once a week. Exenatide is the active ingredient in BYETTA®(exenatide) injection, which is currently available in the U.S. and in manycountries worldwide for people with type 2 diabetes who are unable to achievegood glycemic control with common oral therapies."The exenatide once weekly submission is an important milestone in the overallexenatide development program. The clinical data supporting this submissionhighlight the potential of exenatide once weekly to significantly advance thetreatment of type 2 diabetes," said Daniel M Bradbury, president and chiefexecutive officer of Amylin.